n. an inhibitor of multiple kinases (see protein kinase, tyrosine kinase inhibitor) that blocks the action of vascular endothelial growth factor. It is used for the treatment of advanced renal cell carcinoma and of gastrointestinal stromal tumour after disease progression or on intolerance to imatinib. It is administered orally; its most common side-effects include fatigue, asthenia, gastrointestinal disturbances, hypertension, and bleeding. Trade name: Sutent.
Subjects: Clinical Pharmacology and Therapeutics.